A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets
We identified the first lactylation-ferroptosis cross-talk signature to predict HCC prognosis and identified STMN1/PRDX1 as potential targets for treating HCC by stratifying therapies.
Authors
- Jiali Meng
- Weimei Huang (ORCID: https://orcid.org/0000-0002-2478-284X)
- Rensheng Wang (ORCID: https://orcid.org/0000-0002-0768-9344)
- Qiqi Huang (ORCID: https://orcid.org/0000-0002-5249-8088)
- Xiaolong Li (ORCID: https://orcid.org/0000-0003-1262-346X)
- Ling Li (ORCID: https://orcid.org/0000-0001-5358-4968)
- Changhong Liang (ORCID: https://orcid.org/0000-0001-8267-150X)
Institutions
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Guangxi University of Chinese Medicine (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1677089
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China